Jul 12, 2023

Addressing Pharmacy Benefit Management Misalignment | National Alliance of Healthcare Purchaser Coalitions

There's growing emphasis on the fiduciary responsibility of self-insured employers thanks to the Consolidated Appropriations Act of 2021 (CAA). National Alliance of Healthcare Purchaser Coalitions is out with a call to action for employers to address long-standing conflicts that dog their prescription benefits. Consider the document a playbook for SIEs on what to do in an era where plausible deniability has run its course.

Jul 12, 2023

Eli Lilly’s New Weight-Loss Drug Is Even Better Than Ozempic

Cue payers scrambling to consider how they should cover these meds - and then putting in utilization management based on patients considered highest need. Will be interesting to see what's been learned since the launch of Solvaldi.

May 31, 2023

The International BIO meeting is just two weeks away. Real Endpoints will be moderating three different panels and speaking on a fourth on topics ranging from diversity, equity, and inclusion to gene therapy market access to precision therapy. Make sure to stop by if you are in the BIO neighborhood June 6-8. We’d love to see you!

The International BIO meeting is just two weeks away. Real Endpoints will be moderating three different panels and speaking on a fourth

May 31, 2023

EQRx abandons its mission of drug price reform, will cut more than half of employees

A reminder that it’s hard to change the perverse incentives in the drug value chain.

May 31, 2023

Gene Therapies Are Still Hampered By Substantial Delays Between Approval And Launch

May 12, 2023

Updated: EQRx abandons its mission of drug price reform, will cut more than half of employees

A reminder that it's hard to change the perverse incentives in the drug value chain.

May 12, 2023

Gene Therapies Are Still Hampered By Substantial Delays Between Approval And Launch

This article highlights the commercial challenges facing gene therapies and flicks at a couple of important points that are worth further exploration.

May 12, 2023

Alnylam Issues 2022 Corporate Responsibility Report

For those interested in how biotech and pharma companies communicate about drug value, patient access, and pricing philosophies, corporate responsibility reports are required reading. Many times these reports appear transparent, but aren't given information is averaged across the entire portfolio.

May 12, 2023

Patients Lose Access to Free Medicines Amid Spat Between Drugmakers, Health Plans

Today’s WSJ article on copay alternate funding models (AFM) is the latest in a series of stories in the mainstream media about a game of chicken between drugmakers and payers. It's sure to be a hot topic at #Asembia23, the annual confab happening now in Las Vegas focused on all things specialty drug related.

May 12, 2023

RE Assist Tool: Solving the Medicare Copay Dilemma

Pharma peeps: is medication co-pay affordability specifically for your Medicare patients a top concern? @Real Endpoints has developed an AI-based tool that might be of interest. Watch the video for more information and reach out to Susan Raiola, Julia Murphy, or Denise Wolff, Pharm D for more.